TP53 mutations can cause increased risk for cancers. Here, the authors
show a noncoding polymorphism in TP53 increases risk of some cancers but delays
onset of others, and in a mouse model show this is via alteration of microRNA
targeting sites that differ in impact depending on the tissue.
